Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media.
Starekova J, Pirasteh A, Reeder SB.
AJR Am J Roentgenol. 2024 Sep;223(3):e2330036. doi: 10.2214/AJR.23.30036. Epub 2023 Nov 15.
Gadolinium-Based Contrast Agent-Related Toxicities.
Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, Rossi Espagnet MC.
CNS Drugs. 2018 Mar;32(3):229-240. doi: 10.1007/s40263-018-0500-1.
Gadolinium Contrast Agent Deposition in Children.
Ouyang M, Bao L.
J Magn Reson Imaging. 2025 Jan;61(1):70-82. doi: 10.1002/jmri.29389. Epub 2024 Apr 10.
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M.
AJNR Am J Neuroradiol. 2016 Jul;37(7):1192-8. doi: 10.3174/ajnr.A4615. Epub 2015 Dec 10.
Editorial Comment: Gadolinium-Based Contrast Agent and the Central Vein Sign.
Rubinstein D.
AJR Am J Roentgenol. 2023 Jan;220(1):125. doi: 10.2214/AJR.22.28454. Epub 2022 Sep 7.
Gadolinium as an MRI contrast agent.
Kim HK, Lee GH, Chang Y.
Future Med Chem. 2018 Mar 1;10(6):639-661. doi: 10.4155/fmc-2017-0215. Epub 2018 Feb 7.
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M, Branch S.
Biometals. 2016 Jun;29(3):365-76. doi: 10.1007/s10534-016-9931-7. Epub 2016 Apr 6.
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P.
Arch Toxicol. 2022 Feb;96(2):403-429. doi: 10.1007/s00204-021-03189-8. Epub 2022 Jan 8.
Gadolinium contrast agent selection and optimal use for body MR imaging.
Guglielmo FF, Mitchell DG, Gupta S.
Radiol Clin North Am. 2014 Jul;52(4):637-56. doi: 10.1016/j.rcl.2014.02.004. Epub 2014 Apr 2.
Gadolinium-based contrast agent exposures and physical and cognitive disability in multiple sclerosis.
Nakamura K, McGinley MP, Jones SE, Lowe MJ, Cohen JA, Ruggieri PM, Ontaneda D.
J Neuroimaging. 2023 Jan;33(1):85-93. doi: 10.1111/jon.13057. Epub 2022 Oct 1.
